[go: up one dir, main page]

IL153505A0 - Dds compound and process for the preparation thereof - Google Patents

Dds compound and process for the preparation thereof

Info

Publication number
IL153505A0
IL153505A0 IL15350501A IL15350501A IL153505A0 IL 153505 A0 IL153505 A0 IL 153505A0 IL 15350501 A IL15350501 A IL 15350501A IL 15350501 A IL15350501 A IL 15350501A IL 153505 A0 IL153505 A0 IL 153505A0
Authority
IL
Israel
Prior art keywords
preparation
dds compound
dds
compound
Prior art date
Application number
IL15350501A
Other languages
English (en)
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of IL153505A0 publication Critical patent/IL153505A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL15350501A 2000-06-29 2001-06-27 Dds compound and process for the preparation thereof IL153505A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000195919 2000-06-29
PCT/JP2001/005498 WO2002000734A1 (fr) 2000-06-29 2001-06-27 Compose dds et son procede de preparation

Publications (1)

Publication Number Publication Date
IL153505A0 true IL153505A0 (en) 2003-07-06

Family

ID=18694503

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15350501A IL153505A0 (en) 2000-06-29 2001-06-27 Dds compound and process for the preparation thereof

Country Status (12)

Country Link
US (1) US20030166513A1 (ja)
EP (1) EP1298145A4 (ja)
KR (1) KR20030031502A (ja)
CN (1) CN1449412A (ja)
AU (1) AU2001267831A1 (ja)
BR (1) BR0112287A (ja)
CA (1) CA2412582A1 (ja)
IL (1) IL153505A0 (ja)
MX (1) MXPA02012791A (ja)
NO (1) NO20026212L (ja)
WO (1) WO2002000734A1 (ja)
ZA (1) ZA200300743B (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0774120B1 (de) 1994-07-25 2009-08-26 Roche Diagnostics GmbH Metallchelat-markierte peptide
PL221351B1 (pl) 2012-03-14 2016-03-31 Politechnika Warszawska Sposób otrzymywania nanocząstek polisacharydowych
KR102237639B1 (ko) 2012-10-11 2021-04-07 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
IL320281A (en) 2013-12-25 2025-06-01 Daiichi Sankyo Co Ltd Anti-trop2 antibodies and methods for producing same
PH12020552271A1 (en) 2014-01-31 2022-05-02 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
JP2017114763A (ja) * 2014-03-26 2017-06-29 第一三共株式会社 抗cd98抗体−薬物コンジュゲート
DK3129063T3 (da) 2014-04-10 2021-04-06 Daiichi Sankyo Co Ltd Anti-her3-antistof-lægemiddelkonjugat
EP3130608B1 (en) * 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
US11173213B2 (en) 2015-06-29 2021-11-16 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
FR3045608A1 (fr) * 2015-12-18 2017-06-23 Rhodia Operations Dextrane carboxyle
CN110049779A (zh) 2016-12-12 2019-07-23 第一三共株式会社 抗体-药物缀合物和免疫检查点抑制剂的组合
EP3572428A4 (en) 2017-01-17 2020-12-30 Daiichi Sankyo Company, Limited ANTI-BODY ANTI-GPR20 AND ANTI-BODY-DRUG CONJUGATE ANTI-GPR20
TW202530271A (zh) 2017-05-15 2025-08-01 日商第一三共股份有限公司 抗體-藥物結合物及其用途
KR20250084239A (ko) 2017-08-31 2025-06-10 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 개량 제조 방법
CA3074208C (en) 2017-08-31 2023-10-03 Daiichi Sankyo Company, Limited Novel method for producing antibody-drug conjugate
US12479926B2 (en) 2018-05-18 2025-11-25 Daiichi Sankyo Co., Ltd. Anti-MUC1 antibody-drug conjugate
WO2020022475A1 (ja) 2018-07-27 2020-01-30 第一三共株式会社 抗体-薬物コンジュゲートの薬物部位を認識する蛋白質
US12220604B2 (en) 2018-07-31 2025-02-11 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of an antibody-drug conjugate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69425464T2 (de) * 1993-02-26 2001-05-23 Drug Delivery System Institute, Ltd. Polysaccharidderivat und wirkstoffträger
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
TW409058B (en) * 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
EA003398B1 (ru) * 1998-05-22 2003-04-24 Дайити Фармасьютикал Ко., Лтд. Лекарственный комплекс c полимерным носителем
HK1042438A1 (zh) * 1998-10-30 2002-08-16 第一制药株式会社 Dds化合物及其测定方法
CN1556712A (zh) * 2000-07-13 2004-12-22 ��һ��������ҩ��ʽ���� 含dds化合物的药用组合物

Also Published As

Publication number Publication date
CN1449412A (zh) 2003-10-15
ZA200300743B (en) 2004-02-10
AU2001267831A1 (en) 2002-01-08
EP1298145A4 (en) 2004-12-08
CA2412582A1 (en) 2002-01-03
MXPA02012791A (es) 2003-12-11
NO20026212L (no) 2003-02-06
US20030166513A1 (en) 2003-09-04
WO2002000734A1 (fr) 2002-01-03
NO20026212D0 (no) 2002-12-23
BR0112287A (pt) 2003-05-06
EP1298145A1 (en) 2003-04-02
KR20030031502A (ko) 2003-04-21

Similar Documents

Publication Publication Date Title
IL146105A0 (en) 5-pyridyl-1, 3-azole compounds, process for producing the same and use thereof
AU8405201A (en) Contraception process and administration form for the same
IL153505A0 (en) Dds compound and process for the preparation thereof
AU7773001A (en) Acylacetonitriles, process for preparation thereof and miticides containing the same
PL361234A1 (en) Aqueous formulations and process for preparing the same
IL145520A0 (en) Flame-retarding composition and process for the preparation thereof
IL187126A0 (en) Process for the preparation of 4 - haloalkylnicotinonitriles
AU8824201A (en) Process for the preparation of dinapsoline
IL139023A0 (en) Process for the preparation of 2,3,5-trimethyl-p- benzoquinone
HUP0401577A3 (en) Process for the preparation of 2,4-didezoxyhexoses and 2,4,6-tridezoxyhexoses
HUP0202865A3 (en) Process for the preparation of 2-cyanopyridines
EG22846A (en) Process for the preparation of urea
IL150897A0 (en) Process for the preparation of acetyl-amidiniophenylalanyl cyclohexylglycyl-pyridinioalaninamides
IL138691A (en) Process for the preparation of 3-acyl-indoles
HUP0105166A3 (en) Substances wk-5344a and wk-5344b and process for producing the same
GB9823835D0 (en) Component for vaccine
IL190807A0 (en) Process for the preparation of 2-aminoethylpyridines
IL137364A (en) Process for the preparation of 6,6-dimethylhept-1-en-4-yn-3-ol
EG22758A (en) Process for the preparation of urea
EP1299396A4 (en) NOVEL CEPHALOSPORIN COMPOUNDS AND PROCESSES FOR THE PREPARATION THEREOF
AU4781000A (en) 6-hydroxy-2-naphthylcarbinol and process for the preparation thereof
GB0012249D0 (en) Process for the preparation of 11-oxaprostaglandins
AU2002221114A1 (en) Novel ss-lactam compounds and process for preparing the same
HUP0201518A3 (en) Process for the preparation of tetrafluorohalogenbenzenes
IL147918A0 (en) Process for the preparation of isotretinoin